AstraZeneca is posting bearish reversal signals

The failure to confirm the upside breakout of former 2020 top area at 9200 is a significant sign of weakness

Charts (2)

AstraZeneca, which produces pharmaceutical and medical products, posted 1H results: "Total Revenue increased by 12% (14% at CER) to 12,629 million dollars in the half, with growth across all three therapy areas and in every region. (...) Reported EPS of 1.17 dollars in the half, representing an increase of 108% (106% at CER). Core EPS increased by 24% (26% at CER) to 2.01 dollars. (...) An unchanged first interim dividend of 0.90 dollar per share." The company confirmed 2020 guidance.

From a chartist point of view, the failure to confirm the upside breakout of former 2020 top area at 9200 is a significant sign of weakness. In addition, the stock is posting a Dark Cloud Cover: a bearish reversal candlestick pattern while at the same time the weekly RSI is posting a bearish divergence: both are strong signals likely to favour a downturn. As a consequence, traders might consider short position below 50% retracement of the decline since the top (invalidation level of the candlestick pattern) at 9300 to target a decline towards June bottom area at 8100 and even January top at 7800. Alternatively, an upside breakout of 9300 would lower the immediate corrective risk and favour another test of the 10k area.

Source: GAIN Capital, TradingView

More from Equities

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.